AU2014216349B2 - Methods and diets to protect against chemotoxicity and age related illnesses - Google Patents

Methods and diets to protect against chemotoxicity and age related illnesses Download PDF

Info

Publication number
AU2014216349B2
AU2014216349B2 AU2014216349A AU2014216349A AU2014216349B2 AU 2014216349 B2 AU2014216349 B2 AU 2014216349B2 AU 2014216349 A AU2014216349 A AU 2014216349A AU 2014216349 A AU2014216349 A AU 2014216349A AU 2014216349 B2 AU2014216349 B2 AU 2014216349B2
Authority
AU
Australia
Prior art keywords
diet
protein
low protein
calories
day
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
AU2014216349A
Other languages
English (en)
Other versions
AU2014216349A1 (en
Inventor
Sebastian BRANDHORST
Morgan Elyse Levine
Valter D. Longo
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Southern California USC
Original Assignee
University of Southern California USC
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Southern California USC filed Critical University of Southern California USC
Publication of AU2014216349A1 publication Critical patent/AU2014216349A1/en
Application granted granted Critical
Publication of AU2014216349B2 publication Critical patent/AU2014216349B2/en
Priority to AU2020200297A priority Critical patent/AU2020200297B2/en
Priority to AU2022202764A priority patent/AU2022202764A1/en
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/40—Complete food formulations for specific consumer groups or specific purposes, e.g. infant formula
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A23L33/155—Vitamins A or D
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/17—Amino acids, peptides or proteins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES, NOT OTHERWISE PROVIDED FOR; PREPARATION OR TREATMENT THEREOF
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A61K31/197—Carboxylic acids, e.g. valproic acid having an amino group the amino and the carboxyl groups being attached to the same acyclic carbon chain, e.g. gamma-aminobutyric acid [GABA], beta-alanine, epsilon-aminocaproic acid or pantothenic acid
    • A61K31/198—Alpha-amino acids, e.g. alanine or edetic acid [EDTA]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/401—Proline; Derivatives thereof, e.g. captopril
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4172—Imidazole-alkanecarboxylic acids, e.g. histidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/205—Amine addition salts of organic acids; Inner quaternary ammonium salts, e.g. betaine, carnitine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A61K31/22—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin
    • A61K31/23—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids of acyclic acids, e.g. pravastatin of acids having a carboxyl group bound to a chain of seven or more carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A61K31/405—Indole-alkanecarboxylic acids; Derivatives thereof, e.g. tryptophan, indomethacin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nutrition Science (AREA)
  • Mycology (AREA)
  • Polymers & Plastics (AREA)
  • Epidemiology (AREA)
  • Hematology (AREA)
  • Immunology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pediatric Medicine (AREA)
  • Microbiology (AREA)
  • Biotechnology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biochemistry (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Obesity (AREA)
  • Emergency Medicine (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Endocrinology (AREA)
AU2014216349A 2013-02-12 2014-02-12 Methods and diets to protect against chemotoxicity and age related illnesses Active AU2014216349B2 (en)

Priority Applications (2)

Application Number Priority Date Filing Date Title
AU2020200297A AU2020200297B2 (en) 2013-02-12 2020-01-15 Methods and diets to protect against chemotoxicity and age related illnesses
AU2022202764A AU2022202764A1 (en) 2013-02-12 2022-04-27 Methods and diets to protect against chemotoxicity and age related illnesses

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201361763797P 2013-02-12 2013-02-12
US61/763,797 2013-02-12
PCT/US2014/016025 WO2014127000A2 (en) 2013-02-12 2014-02-12 Methods and diets to protect against chemotoxicity and age related illnesses

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020200297A Division AU2020200297B2 (en) 2013-02-12 2020-01-15 Methods and diets to protect against chemotoxicity and age related illnesses

Publications (2)

Publication Number Publication Date
AU2014216349A1 AU2014216349A1 (en) 2015-08-06
AU2014216349B2 true AU2014216349B2 (en) 2019-10-24

Family

ID=51297596

Family Applications (3)

Application Number Title Priority Date Filing Date
AU2014216349A Active AU2014216349B2 (en) 2013-02-12 2014-02-12 Methods and diets to protect against chemotoxicity and age related illnesses
AU2020200297A Active AU2020200297B2 (en) 2013-02-12 2020-01-15 Methods and diets to protect against chemotoxicity and age related illnesses
AU2022202764A Abandoned AU2022202764A1 (en) 2013-02-12 2022-04-27 Methods and diets to protect against chemotoxicity and age related illnesses

Family Applications After (2)

Application Number Title Priority Date Filing Date
AU2020200297A Active AU2020200297B2 (en) 2013-02-12 2020-01-15 Methods and diets to protect against chemotoxicity and age related illnesses
AU2022202764A Abandoned AU2022202764A1 (en) 2013-02-12 2022-04-27 Methods and diets to protect against chemotoxicity and age related illnesses

Country Status (12)

Country Link
US (3) US9237761B2 (enExample)
EP (2) EP3510875B1 (enExample)
JP (2) JP6885671B2 (enExample)
KR (1) KR20150124962A (enExample)
CN (3) CN109187991B (enExample)
AU (3) AU2014216349B2 (enExample)
BR (1) BR112015019223A2 (enExample)
CA (1) CA2900782C (enExample)
ES (1) ES2807781T3 (enExample)
MX (1) MX382484B (enExample)
RU (2) RU2018141475A (enExample)
WO (1) WO2014127000A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2909802B1 (en) * 2012-10-22 2020-08-12 University of Southern California Diet formulations promoting tissue/organ regeneration
US9237761B2 (en) * 2013-02-12 2016-01-19 University Of Southern California Methods and diets for lowering glucose and/or IGF-1 levels
RU2672594C2 (ru) 2013-07-01 2018-11-16 Юниверсити Оф Саутерн Калифорния Состояние воздержания от пищи в качестве диетического лечения диабета
US10172839B2 (en) 2014-03-06 2019-01-08 University Of Southern California Use of short term starvation regimen in combination with kinase inhibitors to enhance traditional chemo-drug efficacy and feasibility and reverse side effects of kinases in normal cells and tissues
MX2016012896A (es) 2014-04-02 2017-05-12 Univ Southern California Autoinmunidad y tratamiento de la esclerosis multiple.
WO2016130901A2 (en) 2015-02-12 2016-08-18 University Of Southern California Blockers of the growth hormone receptor in disease prevention and treatment
CA2982875C (en) * 2015-04-16 2021-10-19 University Of Southern California Fasting mimicking diet (fmd) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone
RU2724525C2 (ru) * 2015-05-06 2020-06-23 Юниверсити Оф Саутерн Калифорния Способ лечения повышенных уровней инсулина или глюкозы с использованием гипокалорийного или бескалорийного рациона или рациона, имитирующего воздержание от пищи
WO2017097865A1 (en) * 2015-12-07 2017-06-15 Istituto Europeo Di Oncologia Combination of caloric restriction (cr) or igf1/insulin receptor inhibitor with lsd1 inhibitor
CA3224535A1 (en) * 2016-01-12 2017-07-20 University Of Southern California Use of long-term fasting mimicking as dietary treatment for multiple myeloma and other cancers
MX2018009849A (es) 2016-02-15 2018-11-09 Univ Southern California Combinaciones de farmacos y metodos para estimular regeneracion de tipo embrionaria para tratar diabetes y otras enfermedades.
MX2018013727A (es) * 2016-05-11 2019-08-29 Univ Southern California Dieta imitadora del ayuno (fmd) como un tratamiento inmunoregulador para enfermedades gastrointestinales autoinmunes/inflamatorias.
IT201700008499A1 (it) * 2017-01-26 2018-07-26 Univ Degli Studi Genova Composizione dietetica per la prevenzione e/o il trattamento dell’iperplasia dell’endometrio
US11284640B2 (en) * 2017-02-14 2022-03-29 University Of Southern California Fasting mimicking diet
WO2019178486A1 (en) * 2018-03-15 2019-09-19 University Of Southern California Fasting-mimicking diet (fmd) but not water-only fasting promotes reversal of inflammation and ibd pathology
AU2019280170B2 (en) * 2018-06-07 2024-03-28 Société des Produits Nestlé S.A. Methods and compositions for increasing ketone bodies in animals
US20210267250A1 (en) 2018-07-18 2021-09-02 Andreas Michalsen Effects of a short-term fasting mimicking diet on quality of life and tolerance to chemotherapy in patients with cancer
JP2020059699A (ja) * 2018-10-04 2020-04-16 株式会社明治 難治性癌の食事療法およびそれに適した治療食
EP3876741A4 (en) 2018-11-09 2022-08-31 L-Nutra NUTRIENT BAR FOR INTERMITTENT FASTING SIMULATE
CN114096164A (zh) 2019-04-30 2022-02-25 南加利福尼亚大学 作为阿尔茨海默病(ad)的干预措施的禁食模拟饮食(fmd)
IT201900009954A1 (it) * 2019-06-24 2020-12-24 Fondazione Irccs Istituto Naz Dei Tumori Preparazione alimentare a basso contenuto calorico per l’alimentazione di pazienti affetti da neoplasie
CN112273641A (zh) * 2019-07-23 2021-01-29 中国科学院上海营养与健康研究所 一种非节食性的高低蛋白食物交替使用有效干预糖尿病的方法
US20230037534A1 (en) * 2019-12-16 2023-02-09 University Of Southern California Utilization of a fasting-mimicking diet to reduce senescent cells and inflammation
US20230000888A1 (en) * 2019-12-19 2023-01-05 Leibniz-Institut Für Alternsforschung - Fritz-Lipmann-Institut E.V. (Fli) Nad-precursors and dietary restriction for treating age related medical conditions
IT202000008740A1 (it) 2020-04-23 2021-10-23 L Nutra Inc Composizione dietetica per l’incremento della massa magra e della massa muscolare
US12029231B2 (en) * 2020-07-13 2024-07-09 L-Nutra Inc. Method for the treatment of depression
IT202000016957A1 (it) 2020-07-13 2022-01-13 Univ Degli Studi Di Palermo Composizione dietetica per il trattamento della depressione
AU2020468941A1 (en) * 2020-09-23 2023-03-23 Aminovita S.L. Metabolic cancer therapy
TW202227113A (zh) 2020-12-01 2022-07-16 南加州州立大學 模擬禁食飲食提升急性淋巴母細胞白血病模型中的無癌存活
CN114631628A (zh) * 2020-12-15 2022-06-17 中国科学院上海营养与健康研究所 一种增加血液fgf21浓度的方法
CN114631629A (zh) * 2020-12-15 2022-06-17 中国科学院上海营养与健康研究所 一种低蛋白治疗肥胖的方法
CN114794487A (zh) * 2021-01-22 2022-07-29 中国科学院上海营养与健康研究所 一种治疗糖尿病的方法
WO2024044036A1 (en) * 2022-08-23 2024-02-29 University Of Southern California Dietary compositions to extend longevity while maximizing strength and function
WO2025129163A1 (en) * 2023-12-14 2025-06-19 L-Nutra Inc. Longevity extending consumable products for maximizing strength and function, methods of consumption and manufacture

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6406853B1 (en) * 1999-12-23 2002-06-18 The Regents Of The University Of California Interventions to mimic the effects of calorie restriction
US20030152947A1 (en) * 2001-06-15 2003-08-14 Crossman David C. Methods for detecting and treating the early onset of aging-related conditions
US20040081678A1 (en) * 2002-08-09 2004-04-29 Anthony Cincotta Therapeutic process for the treatment of obesity and associated metabolic disorders
US20050031671A1 (en) * 2003-08-06 2005-02-10 James Johnson Weight management, longevity and health paradigm
MX2007007898A (es) * 2004-12-27 2007-08-20 Nestec Sa Uso de formula para lactantes con contenido de proteina reducido.
US20070231371A1 (en) * 2006-02-01 2007-10-04 Nestec, S. A. Nutritional system and methods for increasing longevity
CA3045883C (en) * 2008-04-24 2022-06-28 University Of Southern California Dietary compositions and methods for protection against chemotherapy, radiotherapy, oxidative stress, and aging
CN101385543A (zh) * 2008-10-23 2009-03-18 上海交通大学 低蛋白食品及其制备方法
WO2011050302A2 (en) * 2009-10-22 2011-04-28 University Of Southern California Methods and nutritional formulations to increase the efficacy and reduce the side effects of cancer treatment
EP2909802B1 (en) * 2012-10-22 2020-08-12 University of Southern California Diet formulations promoting tissue/organ regeneration
US9237761B2 (en) * 2013-02-12 2016-01-19 University Of Southern California Methods and diets for lowering glucose and/or IGF-1 levels

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
LUIGI FONTANA ET AL, "Long-term effects of calorie or protein restriction on serum IGF-1 and IGFBP-3 concentration in humans", AGING CELL, GB, (2008-10-01), vol. 7, pages 681 - 687 *
STEPHEN R. SPINDLER, "Caloric restriction: From soup to nuts", AGEING RESEARCH REVIEWS, NL, (2010-07-01), vol. 9, no. 3, doi:10.1016/j.arr.2009.10.003, ISSN 1568-1637, pages 324 - 353 *

Also Published As

Publication number Publication date
HK1212028A1 (en) 2016-06-03
JP2020073473A (ja) 2020-05-14
CN105008929B (zh) 2018-10-02
CN109187991B (zh) 2021-12-24
US9237761B2 (en) 2016-01-19
CA2900782C (en) 2022-09-27
US20140227373A1 (en) 2014-08-14
CN114236130A (zh) 2022-03-25
US20170035094A1 (en) 2017-02-09
JP6885671B2 (ja) 2021-06-16
EP2956776A2 (en) 2015-12-23
BR112015019223A2 (pt) 2017-07-18
AU2020200297B2 (en) 2022-04-07
EP2956776A4 (en) 2016-12-21
MX2015010320A (es) 2016-06-02
RU2018141475A (ru) 2019-03-21
RU2018141475A3 (enExample) 2022-03-29
MX382484B (es) 2025-03-13
CN105008929A (zh) 2015-10-28
CA2900782A1 (en) 2014-08-21
ES2807781T3 (es) 2021-02-24
WO2014127000A2 (en) 2014-08-21
RU2674681C2 (ru) 2018-12-12
CN109187991A (zh) 2019-01-11
EP3510875B1 (en) 2020-06-10
EP3510875A1 (en) 2019-07-17
RU2015134780A (ru) 2017-03-20
US20160331016A1 (en) 2016-11-17
AU2014216349A1 (en) 2015-08-06
AU2020200297A1 (en) 2020-02-06
KR20150124962A (ko) 2015-11-06
AU2022202764A1 (en) 2022-05-19
JP2016509994A (ja) 2016-04-04

Similar Documents

Publication Publication Date Title
AU2020200297B2 (en) Methods and diets to protect against chemotoxicity and age related illnesses
US20240298689A1 (en) Fasting condition as dietary treatment of diabetes
Brandhorst et al. Short-term calorie and protein restriction provide partial protection from chemotoxicity but do not delay glioma progression
US20210137856A1 (en) Fasting mimicking diet (fmd) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone
AU2017207370B2 (en) Use of long-term fasting mimicking as dietary treatment for multiple myeloma and other cancers
HK40002950B (zh) 为受试者提供合理蛋白质膳食的方法
HK40002950A (en) Method for providing reasonable protein diet to subject
HK1212028B (en) Methods and diets to protect against chemotoxicity and age related illnesses
HK40100962A (en) Fasting mimicking diet (fmd) and glucose lowering drugs protect normal cells and generate cancer sensitizing conditions in response to standard and high glucose conditions induced by rapamycin and dexamethasone

Legal Events

Date Code Title Description
FGA Letters patent sealed or granted (standard patent)